Kyprolis Now Covered in Ontario

Myeloma Canada is pleased to announce that as of April 30, Kyprolis (carfilzomib) is now covered by Cancer Care Ontario. The eligibility criteria are as follows:   Carfilzomib (triplet therapy) – in combination with lenalidomide and dexamethasone for multiple myeloma patients who have received at least one prior treatment.   Carfilzomib (doublet therapy) – in combination with dexamethasone for multiple myeloma patients who have received at least one prior treatment.

In addition, all of the following criteria must be met: The patient’s health did not improve within 60 days of completing bortezomib or lenalidomide-based treatment If treated with lenalidomide, the patient did not discontinue treatment due to adverse events or progression within the first 3 months of treatment  If the patient was most recently treated with lenalidomide, his health has not improved while on treatment

This is now the third province to fund Kyprolis (after British Columbia and Manitoba)  and we would like to thank each and every one  of you who took part in our advocacy efforts to date by taking part in the MAP campaign. We also encourage those living in other provinces to continue writing to get Kyprolis funded in your province. For more information, visit: www.myelomacommunity.ca

‌ ‌ ‌ ‌ ‌